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Visual abstract  
Key question: 
Does RIPC confer cardioprotection in patients undergoing CABG or AVR surgery? 
Key findings: 
RIPC does not ameliorate cardiac injury, metabolic stress, and inflammatory response during 
CABG or AVR surgery. 
Take home message  
This trial supports the view that RIPC does not confer additional cardioprotection in patients 
undergoing isolated CABG or AVR surgery.  
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ABSTRACT  
Objective: This trial was designed and started recruiting at a time when the benefits of 
remote ischemic preconditioning during open-heart surgery were still controversial. We 
focused on a homogeneous patient’s population undergoing either isolated aortic valve 
replacement (AVR) or coronary artery bypass graft surgery (CABG) by investigating cardiac 
injury, metabolic stress and inflammatory response.  
Methods: A two-centre randomised controlled trial recruited a total of 124 patients between 
February 2013 and April 2015. Of these 64 patients underwent CABG and 60 patients AVR. 
Patients were randomized to either sham or preconditioning. Remote ischemic 
preconditioning was applied following anesthesia and before sternotomy. Myocardial injury 
and inflammatory response were assessed by serially measuring cardiac troponin I, and IL-6, 
8, 10 and TNF-α. Biopsies from left and right ventricles were harvested after ischemic 
reperfusion injury for nucleotides analysis. 
Results: Application of remote ischemic preconditioning did not alter troponin I release, 
levels of inflammatory markers and cardiac energetics in both CABG or AVR groups.  
Conclusions: Preconditioning did not confer any additional cardioprotection in terms of 
troponin I, inflammatory markers reduction, and left and right ventricle energy metabolites 
preservation in patients undergoing isolated coronary artery bypass grafting or aortic valve 
surgery.  
 
Key words: remote ischemic preconditioning; coronary artery bypass grafting; aortic valve 
replacement; cardiac injury. 
 
 
 
 
 
 
  4 
INTRODUCTION 
Two recent large randomized trials have shown neither troponin reduction nor clinical benefit 
in patients undergoing cardiac surgery after upper limb remote ischemic preconditioning 
(RIPC)1-2.  Different confounders, heterogeneous population of patients with different 
pathologies and a variety of comorbidities may have significantly biased the efficacy of the 
intervention3.  
The mechanisms underlying RIPC protection in experimental models and clinical setting are 
still poorly understood4.  Work in experimental models has monitored changes in cardiac 
metabolites in ventricular biopsies to help understand how this intervention is working5. 
Additionally, knowledge of potential RIPC-induced changes in systemic stress (e.g. 
inflammatory response) would also help in elucidating the effects of RIPC during cardiac 
surgery4.  
Thus, the aim of this trial was to investigate the effect of upper limb RIPC in patients 
undergoing isolated coronary artery bypass grafting (CABG) and aortic valve replacement 
(AVR) on cardiac injury, metabolic stress and inflammatory response.  
 
PATIENTS AND METHODS  
Trial Design 
A two-centre randomised controlled trial investigating the effects of RIPC in patients 
undergoing: a) isolated CABG and b) isolated AVR with cardiopulmonary bypass (CPB) and 
cardioplegic arrest. The research objectives were addressed by randomising participants 
within each of four patient’s strata to RIPC or SHAM control. The randomisation was carried 
out by the research nurse, who carried out both interventions in theatre. Participants, 
clinicians and trial personnel were blinded to which group a participant was assigned. The 
study was conducted at the Hammersmith Campus of Imperial College Healthcare NHS Trust 
and the University Hospitals of Bristol NHS Foundation Trust. The study was approved by 
the London-Harrow Research Ethics Committee (reference No. REC No: 12/LO/1361), and 
registered to the International Standard Randomized Controlled Trial Number (ISRCTN) 
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registry with the ID 33084113 (DOI 10.1186/ISRCTN33084113) and to the UK controlled 
randomized trial number (UKCRN) registry ID 13672. The study was sponsored by the 
Imperial College of London and funded by the British Heart Foundation (BHF) and 
Biomedical Research Unit (BRU)6. The recruitment was carried out from February 2013 till 
April 2015 (CONSORT checklist on line supplement). 
  
Participant and RIPC protocol          
Inclusion, exclusion criteria and trial conduct were published before6 (supplementary data). 
RIPC was induced as described by others1,7. Briefly, RIPC comprised four 5 min cycles of 
upper limb ischemia, induced by a blood pressure cuff inflated to 200 mm Hg, with an 
intervening 5 min of reperfusion by deflating the cuff.  
 
Outcomes 
The study’s primary end point was: troponin I (cTnI) measured at base line (before the 
operation) and 6, 12, 24, 48, 72, hours after aortic cross clamp release. Secondary outcomes 
were: myocardial metabolites measured in snap-frozen biopsies obtained with tru-cut needle 
from the left and right ventricle 20 minutes after index ischemia (aortic cross clamp); blood 
inflammatory markers: interleukin (IL)-6, 8, 12 and tumor necrosis factor (TNF)-α; blood pH; 
systemic metabolic stress assessed by lactate and serum creatinine level. Inflammatory 
markers, lactate and pH were measured at the same time points as for cTnI; serum creatinine 
was measured at baseline and from post-operative day 1 to day 7. Relevant clinical outcomes 
and serious adverse events (SAEs) were also recorded. 
 
Sample size and statistical analysis 
Sample size was estimated from our previous work6 (supplementary data). Analyses were 
performed on an intention-to-treat basis. Shapiro-Wilk test was used to check for the 
normality of data in groups before further analysis. Continuous data are summarized as mean 
± SD or median (interquartile range) if distributions are skewed. Categorical data are 
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summarized as number and percentage. Repeated measures (troponin, inflammatory markers, 
pH, lactate, creatinine) were compared using mixed model, with RIPC as the reference group. 
Model validity was checked using standard methods; if a model fitted poorly, transformations 
were explored. Outcomes analyzed on a logarithmic scale were transformed back to the 
original scale after analysis and results presented as geometric mean ratios (GMR). Ventricle 
biopsies were compared using unpaired, two tailed, t-test or Wilcoxon rank sum test; P < 0.05 
was considered significant. Energy charge was calculated as follow: Energy charge = ATP + 
(0.5 * ADP)/ ATP + ADP + AMP5. 
The trial was not powered to detect differences in clinical outcomes and their frequencies are 
tabulated descriptively. All analyses and plotting were performed in: R Core Team (2014); R: 
A language and environment for statistical computing; R Foundation for Statistical 
Computing, Vienna, Austria. URL http://www.R-project.org (packages used: ‘aov’, 
‘graphics’, ‘lmer’, ‘stat’). 
 
Anaesthesia and surgical management 
Anaesthetic, CPB, cardioplegia, and surgical techniques and any other aspect of pre and post-
operative management were in accordance with existing protocols in use at both centres 
(supplementary data) as previously reported6.  
 
RESULTS 
Recruitment 
Between February 2013 and April 2015, 316 patients were screened at the Hammersmith 
Hospital and Bristol Royal Infirmary Hospital for inclusion in the trial. Sixty-four were 
ineligible (see CONSORT diagram, supplementary figure S1).  Of the 252 eligible patients, 
124 agreed to participate to the study; 64 and 60 patients respectively formed the CABG and 
AVR population that was randomized to RIPC / SHAM. The primary analysis includes all 
randomized participants. Participants were followed for 3 months after randomization. Safety 
data at 3 months were available on all participants. 
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Baseline data 
Overall baseline data are reported in table 1. In the CABG group, patients allocated to SHAM 
when compared with those allocated to RIPC included more individuals with previous 
myocardial infarction (40.6% vs 9.3%), type 2 diabetes mellitus (NIDDM) (40.6% vs 15.6%) 
and higher creatinine (95.1 ± 20.7 and 82 ± 14). In the AVR group patients allocated to RIPC 
compared with those allocated to SHAM had slightly higher creatinine (87.3 ± 22 and 78.6 ± 
16.2). Four patients underwent unplanned concomitant CABG. The surgeons performing the 
procedures on reviewing the coronary angiogram after randomization, felt that the degree of 
coronary stenosis was significant, hence the need for additional CABG.  Those patients were 
included as per intention to treat analysis (3 in RIPC group and 1 in SHAM group). 
Preoperative medications are reported in supplementary table T1.  
 
Operative details 
Operative details are illustrated in table 2. In both CABG and AVR there was no difference in 
RIPC or SHAM group in cross-clamp, CPB time and the overall duration of the surgical 
procedure. There was no in-hospital mortality. Post-operative complications are described in 
table 3 and 4. No serious adverse events were recorded.  
 
cTnI release  
CABG group: Troponin I concentrations are illustrated in Figure 1a and summarized in 
supplementary table T2. Preoperative concentrations were similar in the 2 groups (30 out of 
32 [93.7%] below the detectable limit, median concentration 0.25 ng/L among participants 
with detectable concentrations in the RIPC group vs 30 out of 32 [93.7%] and 0.007 ng/L in 
the SHAM group). Cardiac troponin I concentrations rose following surgery peaking at 6 
hours and were, on average, 8% lower in the RIPC group (geometrical mean ratio GMR 0.92 
(0.78,0.98), p=0.24). 
Creatinine, pH and lactate concentration are also illustrated in figure 1 (b/c/d). Postoperative 
creatinine, lactate concentrations and blood pH did not significantly differ between the 
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groups; postoperative creatinine concentration was lower in the RIPC group (GMR, 0.85; 
95% CI, 0.83-0.86; P=0.74); pH was slightly lower in the SHAM group (MD, 1; 95% CI, 
0.99 to 1; P=0.26) and lactate were, on average, 7% lower in the RIPC group (GMR, 0.93; 
95% CI, 0.87-0.99; p=0.9). No serious adverse events were recorded.  
AVR group: Troponin I concentrations are illustrated in Figure 2a and summarized in 
supplementary table T3. Preoperative concentrations were similar in the 2 groups (31 out of 
31 [100%] below the detectable limit in the RIPC group, vs 28 out of 29 [96.5%] in the 
SHAM group). Cardiac troponin I concentrations rose following surgery peaking at 6 hours 
and were, on average, 10% lower in the SHAM group (geometrical mean ratio GMR 1.1 
(0.65,1.44), p=0.65). 
Postoperative creatinine, blood pH and lactate concentrations were similar in both groups 
(Figure 2 b/c/d); as was postoperative creatinine concentration (GMR, 1.07; 95% CI, 0.97-
1.17; P=0.56); pH was, on average, 10% lower in the RIPC group (MD, 0.9; 95% CI, 0.89-1; 
p=0.85), while lactate was slightly lower in the SHAM group (GMR, 1.01; 95% CI, 0.89-
1.27; P=0.63).  
 
Inflammatory markers 
The expression of relevant cytokines was assessed using the MILLIPLEX® MAP Human 
High Sensitivity T Cell Magnetic Bead Panel (supplementary data).  
CABG group: Interleukin 6, 8, 10 and TNF-α baseline and post-operative values for both 
groups are depicted in figure 3 a-d. There were no statistically significant differences for each 
inflammatory marker considered (P=0.62, 0.72, 0.73 and 0.81, IL-6, 8, 10 and TNF-α RIPC 
vs SHAM respectively).  
AVR group: Interleukin 6, 8, 10 and TNF-α baseline and post-operative values for both 
groups are depicted in figure 4 a-d. There were no differences for each inflammatory marker 
considered (P=0.84, 0.43, 0.5 and 0.28, IL-6, 8, 10 and TNF-α RIPC vs SHAM respectively). 
 
Cardiac metabolites 
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The metabolites measured were: ATP (adenosine triphosphate), ADP adenosine diphosphate, 
AMP (adenosine monophosphate). They were measured using high-performance liquid 
chromatography (HPLC) as previously described5 (supplementary data). The specimens were 
all of high quality with wet weight 2.6 (1.8) and 2.9 (2) mg for CABG and AVR respectively. 
CABG group: The analysis of the adenine nucleotides of the left and right ventricle biopsies 
are illustrated in supplementary figure S2 and summarized in supplementary table T4. No 
statistical difference was observed at the level of the left and right ventricles in terms of 
phosphorylation potential (P=0.84, 0.76, 0.71, 0.92, ATP/ADP, ATP/AMP, left and right 
ventricle RIPC vs SHAM respectively) and cardiomyocytes energy charge between 
RIPC/SHAM group after ischemic reperfusion injury (P=0.65, 0.88, left and right ventricle 
RIPC vs SHAM respectively). 
AVR group: The analysis of the adenine nucleotides of the left and right ventricle biopsies are 
illustrated in supplementary figure S3 and summarized in supplementary table T4. No 
statistical difference was observed at the level of the left and right ventricles in terms of 
phosphorylation potential (P=0.74, 0.67, 0.50, 0.89, ATP/ADP, ATP/AMP, left and right 
ventricle RIPC vs SHAM respectively) and cardiomyocytes energy charge between 
RIPC/SHAM group after ischemic reperfusion injury (P=0.96, 0.78, left and right ventricle 
RIPC vs SHAM respectively). 
 
DISCUSSION 
To the best of our knowledge this is the first study in human that investigate the effect of 
RIPC on troponin, inflammatory markers and myocytes metabolites of left and right ventricle 
in two different cardiac pathologies.  
Preconditioning did not to confer any additional cardio-protection in term of troponin I, 
inflammatory markers reduction, and left and right ventricle energy metabolites preservation. 
These findings are in line with the report of the two largest prospective trials on RIPC in 
cardiac surgery1,2. 
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The ERICCA trial recruited high-risk patients undergoing CABG ± AVR and failed to detect 
any benefit in the group randomized to RIPC1. The RIPHeart study led to the same 
conclusions2. Same neutral findings were reported by the most recent meta-analysis by the 
Remote reconditioning Trialists’ Group, which included 23 trials of RIPC with a total of 2200 
patients undergoing cardiovascular surgery8.  
Coronary artery and aortic valve disease are associated with specific disease-induced cellular 
remodeling, since they may exhibit specific cellular proteome and may response differently to 
ischemic reperfusion injury9. Similarly, left and right ventricle may have, as previously 
demonstrated, different protein profile9. Different Authors 10-12, upon calculating markers of 
ischemic stress including phosphorylation potential and energy charge, found RIPC to have 
significant effect. On the contrary we previously reported that RIPC was associated with 
lower phosphorylation potential compared to control in mice, after RIPC but before ischemic 
reperfusion injury5.  
Neutral results were observed in our study in both diseases in left and right ventricle biopsies 
questioning the uncritical interpretation of results from experimental clinical models to the 
clinical scenario.  
Ischemic reperfusion injury and CPB used during cardiac surgery elicit systemic 
inflammatory responses that may ultimately contribute to myocardial dysfunction and 
postoperative complications13. Accordingly, it has been proposed that RIPC confers systemic 
protection by eliciting an anti-inflammatory response and anti-apoptotic gene activation13-15. 
In our study we did not find any significant differences in terms of pro and anti-inflammatory 
cytokines in both pathologies.  
There are many confounders that may undermine the effect of RIPC4. Patients with coronary 
disease may be already ‘naturally preconditioned’ by previous episode of transient ischemia. 
There are evidences that both propofol and volatile (e.g. sevoflurane) anesthetic regime used 
in heart surgery may elicit cardio-protection16. As the ERICCA trial, we included both 
anesthetic regimens while in the RIPHeart only propofol based anesthesia was used.  
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It may be plausible that RIPC may be associated with some harmful events17. We did not find 
any difference in clinical outcomes but our study was not powered to achieve this. 
This study had several strengths. It was a two-centred prospective double-blinded randomised 
trial that used a sham control (inflation of the cuff under the surgical drape beside the patient) 
to prevent surgeon or physician bias. It included 2 different populations with specific 
diseases; in the AVR stratum, patients had normal coronary artery physiology with no 
anticipated natural preconditioning, whereas a certain degree of natural preconditioning 
phenomena was expected in the CABG group due to previous angina. It also investigated the 
effect of RIPC in two different proteonomic scenarios (coronary disease and aortic valve 
disease) in left and right ventricles biopsies. Furthermore, the study has strong elements of 
novelty: it compares blood (troponin) and myocardial biomarkers of injury (inflammatory 
response, energy charge, phosphorylation potential) in humans.  
Perhaps the biggest study limitation was the use of both propofol and volatile (sevoflurane) 
anaesthesia regimens during surgery. Both anaesthetic regimens can potentially interfere with 
preconditioning effects. There was also a certain level of heterogeneity with more patients 
with diabetes and history of MI in the SHAM CABG group. Lastly, mid- and long-term 
follow-ups were not conducted in this study; however, survival after surgery has been shown 
to correlate with early troponin release, which was no different in both groups of our study  
 
CONCLUSION 
In patients undergoing isolated CABG or AVR, preconditioning did not seem to confer any 
additional cardioprotection in term of troponin I, inflammatory markers reduction, and left 
and right ventricle energy metabolites preservation. 
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FIGURE LEGEND 
 
Figure 1 a-d. CABG: Concentration over time. Geometric mean and 95% confidence interval 
(CI) at each study time point by group, and geometric mean ratio (GMR) and 95% CI for the 
effect of RIPC versus SHAM on a) troponin, b) creatinine, c) pH and d) lactate. Mean and 
standard deviation (SD) at each study time point by group, and mean difference (MD) and 
95% CI for the effect of RIPC versus SHAM on pH level. CABG: Coronary artery bypass 
grafting. Pre: Preoperative. RIPC: Remote ischemic preconditioning. 
 
Figure 2 a-d. AVR: Concentration over time. Geometric mean and 95% confidence interval 
(CI) at each study time point by group, and geometric mean ratio (GMR) and 95%CI for the 
effect of RIPC versus SHAM on a) troponin, b) creatinine, c) pH and d) lactate. Mean and 
standard deviation (SD) at each study time point by group, and mean difference (MD) and 
95% CI for the effect of RIPC versus SHAM on pH level. AVR: Aortic valve replacement. 
Pre: Preoperative. RIPC: Remote ischemic preconditioning.  
 
Figure 3 a-d. CABG: Concentration over time. Geometric mean and 95% confidence interval 
(CI) at each study time point by group, and geometric mean ratio (GMR) and 95% CI for the 
effect of RIPC versus SHAM on a, b, c) IL-6, 8, 10 and d) TNF-α. CABG: Coronary artery 
bypass grafting. IL: Interleukin. Pre: Preoperative. RIPC: Remote ischemic preconditioning. 
TNF: Tumor necrosis factor.  
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Figure 4 a-d. AVR: Concentration over time. Geometric mean and 95% confidence interval 
(CI) at each study time point by group, and geometric mean ratio (GMR) and 95% CI for the 
effect of RIPC versus SHAM on a, b, c) IL-6, 8, 10 and d) TNF-α. AVR: Aortic valve 
replacement. IL: Interleukin. Pre= Preoperative. RIPC: Remote ischemic preconditioning. 
TNF: Tumor necrosis factor.  
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TABLE 1. Baseline characteristics  
                                           CABG                           AVR      ALL  
 RIPC 
(n=32) 
SHAM 
(n=32) 
Overall 
(n=64) 
RIPC 
(n=31) 
SHAM 
(n=29) 
Overall             
(N=60) 
n=124 
Age (y/o)  63.4±8.9 62.9±16.3 64.1±10.3 71.4±16.8 66.2±12.6 68.9±15 66.4±13 
Male, n (%) 28(87.5) 27(84.3) 55(85.9) 19(61.3) 20(69) 39(65) 94(75.8) 
Body mass index 28.2±4.5 29.2±5.6 28.7±5.1 29.2±6.8 28.7±5.5 29±6.2 28.8±5.6 
NYHA I, n (%) 10(31.2) 12(37.5) 22(34.4) 19(61.3) 20(69) 39(65) 61(49.2) 
NYHA II, n (%) 17(53.1) 18(56.2) 35(54.7) 4(12.9) 2(6.9) 6(10) 41(33) 
NYHA III, n (%)  4(12.5) 2(6.2) 6(9.3) 17(54.8) 19(65.5) 36(60) 42(33.9) 
NYHA IV, n (%) 1(3.1) 0 1(1.6) 10(32.2) 8(27.6) 18(30) 19(15.3) 
CCS I, n (%) 9(28.1) 8(25) 17(26.6) 4(12.9) 6(20.7) 10(16.6) 27(21.7) 
CCS II, n (%)  17(53.1) 19(59.4) 36(56.2) 10(32.2) 7(24.1) 17(28.3) 53(42.7) 
CCS III, n (%)  5(15.6) 3(9.3) 8(12.5) 2(6.4) 0 2(3.3) 10(8) 
CCS IV, n (%) 0 0 0 0 1(3.4) 1(1.6) 1(0.8) 
Previous MI, n (%) 3(9.3) 13(40.6) 16(25) 2(6.4) 0 2(3.3) 18(14.5) 
AF, n (%) 0 0 0 2(6.4) 1(3.4) 3(5) 3(2.4) 
Permanente pacemaker, 
n (%) 
1(3.1) 1(3.1) 2(3.1) 1(3.2) 1(3.4) 2(3.3) 4(3.2) 
LV good >50%, n (%) 26(81.2) 23(71.8) 49(79.6) 26(83.9) 26(89.6) 52(86.6) 101(81.4) 
LV moderate <50 > 
30%, n (%) 
6(18.7) 9(28.1) 15(23.4) 4(12.9) 3(10.3) 7(11.6) 22(17.7) 
LV less < 30%, n (%)  0 0 0 1(3.2) 0 0 1(0.8) 
Smoking, n (%) 15(46.9) 17(53.1) 32(50) 15(48.4) 10(34.5) 25(41.6) 57(46) 
Ex smoking, n (%) 5(15.6) 2(6.2) 8(12.5) 1(3.2) 6(20.7) 7(11.6) 15(12) 
Family history CAD, n 
(%) 
24(75) 23(71.8) 47(73.4) 12(38.7) 13(44.8) 25(41.6) 72(58) 
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Hypercholesterolemia, n 
(%) 
29(90.6) 31(96.9) 60(93.7) 16(51.6) 17(58.6) 33(55) 93(75) 
Hypertension, n (%) 26(81.2) 30(93.7) 56(87.5) 23(74.2) 20(68.9) 43(71.6) 99(79.8) 
Hypothyroidism, n (%) 0 1(3.1) 1(1.6) 3(9.7) 3(10.3) 6(10) 7(5.6) 
COPD, n (%) 5(15.6) 7(21.9) 12(18.7) 3 (9.7) 3 (10.3) 6 (10) 18(14.5) 
CVA/TIA’s (%)  4(12.5) 1(3.1) 5(7.8) 3(9.7) 3(10.3) 6(10) 11(8.9) 
Neurological 
dysfunction, n (%) 
0 0 0 0 1(3.4) 1(1.6) 1(0.8) 
IDDM, n (%) 1(3.1) 3(9.3) 4(6.25) 0 1(3.4) 1(1.6) 5(4) 
NIDDM, n (%) 5(15.6) 13(40.6) 18(28.1) 4(12.9) 4(13.8) 8(13.3) 26(21) 
Extracardiac 
arteriopathy, n (%) 
1(3.1) 0 1(1.6) 1(3.2) 2(6.9) 3(5) 4(3.2) 
Creatinine, mg/dl    82±14 95.1±20.7 88.6±18.7 87.3±22 78.6±16.2 83.1±19.7 85.9±19.3 
Number of CABG  2.7±0.5 2.7±0.5 2.7±0.5 0.1±0.7 0±0 0.08±0.5 1.4±1.4 
Elective, n (%) 28(87.5) 30(9.4) 58(90.6) 29(936) 27(93.1) 56(93.3) 114(92) 
Urgent, n (%) 4(12.5) 2(6.2) 6(9.4) 2(6.4) 2(6.9) 4(6.6) 10(8) 
Values are presented as median (interquartile range), mean ± standard deviation, or n (%). AVR: Aortic valve 
replacement. CABG: Coronary artery bypass grafting. CAD: Coronary artery disease. CCS: Canadian Cardiovascular 
Society. CVA: Cerebral vascular accident.  COPD: Chronic obstructive pulmonary disease. IDDM: Insulin dependent 
diabetes mellitus. LV: Left ventricular function. MI: Myocardial infarction. NIDDM: Non-insulin dependent diabetes 
mellitus. NYHA: New York Heart Association. TIA= Transient ischemic attack. RIPC: Remote ischemic preconditioning. 
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TABLE 2. Intraoperative details 
                                           CABG                               AVR 
 RIPC 
(n=32) 
SHAM 
(n=32) 
Overall 
(n=64) 
RIPC 
(n=31) 
SHAM 
(n=29) 
Overall             
(n=60) 
Operation duration 
(h) (IQR) 
3.6(3-4) 3.7(3.3-4.1) 3.7(3.2-4.1) 3.1(2.9-3.5) 3.1 (2.9-3.4) 3.1(2.9-3.4) 
CCT (min) (IQR) 40.5(32.5-49.5) 42 (33-49) 42 (32.5-49.5) 66(55-79) 63 (52-85) 64 (52-81) 
CPB (min) (IQR) 77.5(71.5-85.5) 85(68.5-95) 79.5(70.5-94) 93(75-112) 91(80-110) 93(77.5-111) 
DC shock after CC 
release, n (%) 
3 (9.3) 1 (3.1) 4 (6.2) 6  (18.7) 7 (24.1) 13 (21.6) 
SR after CC 
release, n (%) 
28 (87.5) 28 (87.5) 56 (87.5) 20 (64.5) 20 (68.9) 40 (66.6) 
IABP, n (%) 1 (3.1) 0 1(1.5) 1 (3.2) 1 (3.4) 2 (3.3) 
Use of tranex, n 
(%) 
23 (71.8) 23 (71.8) 46 (71.8) 27 (87) 25 (86.2) 52 (86.6) 
Intraop RBC 0.06±0.3 0.6±1 0.3±0.8 0.2±0.6 0.03±0.1 0.1±0.3 
Noradrenalin, n (%) 14 (43.7) 11 (34.3) 25 (39) 6 (19.3) 5 (17.2) 11 (18.3) 
Dobutamine, n (%) 0 0 0 0 0 0 
Enoximone, n (%) 1 (3.1) 0 1 (1.5) 3 (9.6) 2 (6.9) 5 (8.3) 
Needs for pace 
maker, n (%) 
1 (3.1) 1(3.1) 2 (3.1) 5 (16.1) 6 (20.6) 11 (18.3) 
Number of CABG  4.4±0.8 4.1±0.9 4.2±0.9 - - - 
Values are presented as median (1st and 3rd interquartile range), mean ± standard deviation, or n (%). AF: Atrial fibrillation. 
AV: Atrio-ventricular. AVR: Aortic valve replacement. CC: Cross clamp. Cryo: Cryoglobulin. CCT: Cross clamp time. CPB: 
Cardio pulmonary bypass. FFP: Fresh frozen plasma. IABP: Intra-aortic balloon pumping. PLT: Platelets. RBC: Red blood 
cells. RIPC: Remote ischemic preconditioning. VF: Ventricle fibrillation. VT: ventricle tachycardia 
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TABLE 3 CABG: Postoperative details  
 Randomised to 
RIPC 
(n = 32) 
Randomised to  
SHAM 
(n = 32) 
Overall 
(n = 64) 
Total ventilation time (h) (IQR) 8 (6–12) 7.5 (5–10) 7.7 (5–12) 
Time in ICU (h) (IQR) 15 (12–18) 9 (3.6–14.4) 12 (8.1–17.1) 
Time on ward (h) (IQR) 3 (2–5) 4 (3–5) 3 (3–5) 
Length of hospital stay (days) (IQR) 6.5 (6–8) 6.5 (6–8) 6.5 (6–8) 
In hospital mortality, n (%) 0 0 0 
Myocardial infarction, n (%)  1 (3.1) 0 1 (1.5) 
ST/AF, n (%) 5 (15.6) 5 (15.6) 10 (15.6) 
VF/VT, n (%) 0 0 0 
Pacing permanent (%) 0 0 0 
Reopening for bleeding (%) 0 1 (3.1) 1 (1.5) 
Inotropes used, n (%) 17 (53.1) 15 (23.4) (50) 
IABP, n (%) 0 0 0 
Vasodilators used, n (%) 8 (25) 6 (18.7) (21.8) 
Low cardiac output, n (%) 0 0 0 
Re-intubation, n (%) 0 0 0 
Tracheostomy, n (%) 0 0 0 
C-PAP mask, n (%) 9 (28.1) 6 (18.7) 15 (18.7) 
Pneumothorax/effusion, n (%) 2 (6.2) 3 (9.3) 5 (7.8) 
Respiratory infection, n (%) 1 (3.1) 1 (3.1) 2 (3.1) 
Hemofiltration/dialysis (%) 0 0 0 
Permanent stroke/TIA, n (%) 0 0 0 
Values are presented as median (1st and 3rd interquartile range), or n (%). There were no missing data. 
AF: Atrial fibrillation. IABP: Intra-aortic balloon pump. ICU, intensive care unit; RIPC: Remote 
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ischemic preconditioning. TIA, transient ischaemic attack. VF: Ventricle fibrillation. VT: Ventricle 
tachycardia. 
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TABLE 4. AVR: Postoperative details  
 Randomised to  
RIPC 
(n = 31) 
Randomised to  
SHAM 
(n = 29) 
Overall  
(n = 60) 
Total ventilation time (h) (IQR) 8 (4–12) 7.2 (5–13) 7.5 (4–13) 
Time in ICU (h) (IQR) 13.2 (9–24) 12 (4.5–20) 12 (6.6–21) 
Time on ward (h) (IQR) 3.5 (3–6) 3 (2–5) 3 (2.5–6) 
Length of hospital stay (days) (IQR) 7 (6–9) 6 (5–8) 7 (6–8.5) 
In hospital mortality, n (%) 0 0 0 
Myocardial infarction, n (%)  0 0 0 
Tachycardia/AF, n (%) 18 (58) 12 (38.7) 30 (50) 
VF/VT, n (%) 0 0 0 
Pacing permanent, n (%) 2 (6.4) 0 2 (3.3) 
Reopening for bleeding, n (%) 1 (3.2) 0 1 (1.6) 
Inotropes used, n (%) 15 (48.3) 17 (58.6) (53.3) 
IABP, n (%) 0 0 0 
Vasodilators used, n (%) 13 (41.9) 10 (34.4) 23 (38.3) 
Low cardiac output, n (%) 1 (3.2) 0 1 (1.6) 
Re-intubation, n (%) 0 1 (3.4) 1 (1.6) 
Tracheostomy, n (%) 0 1 (3.4) 1 (1.6) 
C-PAP mask, n (%) 5 (16.1) 1 (3.4) 6 (10) 
Pneumothorax/effusion, n (%) 1 (3.2) 1 (3.4) 2 (3.3) 
Respiratory infection, n (%) 4 (12.9) 4 (13.7) 8 (13.3) 
New hemofiltration/dialysis, n (%) 0 0 0 
Permanent stroke/ TIA, n (%) 0 0 0 
Values are presented as median (1st and 3rd interquartile range), or n (%). There were no missing data. AF: 
Atrial fibrillation. IABP: Intra-aortic balloon pump. ICU: intensive care unit; RIPC: Remote ischemic 
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preconditioning. TIA: Transient ischaemic attack. VF: Ventricle fibrillation. VT: Ventricle tachycardia. 
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